Ticker

Science-first nutraceutical platform: Every "18" product must clear three criteria before reaching market - a patented ingredient, peer-reviewed clinical evidence, and the exact dose studied in clinical trials; a bar the vast majority of the supplement industry cannot meet Three products introduced, $7.8 billion addressable market: Noor18™, Liv18™, and Cur18™ - targeting healthy aging & beauty, liver & metabolic…

Phase 1 complete: product development, packaging, and initial commercial setup finalized ahead of schedule Production commencing April 2026: GMP-certified, FDA-registered, UL-audited U.S. manufacturing - mitigating tariff risk $5M+ projected annual revenue: Liv18™ expected to generate over $5 million annually at approximately 75% gross margins Direct-to-consumer model: scalable DTC strategy with targeted advertising…

Clinically studied curcumin formulation demonstrating significantly enhanced absorption versus standard 95% curcuminoid extracts. Derived predominantly from turmeric (~98.5%), maintaining a composition closer to the natural profile of the plant.

CHICAGO, IL / ACCESS Newswire / April 16, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the continued integration of artificial intelligence (AI) across its operations, reflecting ongoing investments aimed at enhancing efficiency, reducing costs, improving customer experience, and driving sales growth. AI is…

Scaled contract manufacturing division, securing long-term agreements for over 12 million units Expanded Sky Premium Life portfolio by 60 SKUs and accelerated global expansion, securing purchase orders for over 300,000 units across new markets Advanced R&D pipeline, securing patented anticancer drugs, multiple AI-driven patent filings, and CCX0722 weight management product entering final development Secured $300…